BERLIN, Jan 27 (Reuters) - Swiss pharmaceutical firm Roche said on Tuesday that a phase II clinical trial of its experimental ...
Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.
Success rates in phase II and phase III clinical trials are recognized as two of the most powerful drivers of overall efficiency in drug development (Nat. Rev. Drug Discov. 23, 656–657; 2024). With ...
OASIS+ is a suite of six multiple-award, indefinite-delivery/indefinite-quantity contracts with a five-year base period and a five-year option term. The contract ...
HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck ...
Please provide your email address to receive an email when new articles are posted on . One in six participants in phase 2 cancer trials received a therapy that gained FDA approval. The results ...
The General Services Administration has launched the second phase of the One Acquisition Solution for Integrated Services Plus, or OASIS+, contract program, adding five new service domains as part of ...
BERLIN, Jan 27 (Reuters) - Swiss pharmaceutical firm Roche said on Tuesday that a phase II clinical trial of its experimental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results